Corvus Pharmaceuticals, Inc. cotiza a 10.05 USD y tiene una capitalización bursátil de $845M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent in…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.19 | $-0.15 | $-0.15 |
| Estimado | $-0.21 | $-0.17 | $-0.15 | $-0.13 |
| Sorpresa | — | -11.8% | +0.0% | -15.4% |
| Métrica | CRVS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -25.0% | -40.4% | +15.4% |
| ROA | -21.5% | -32.0% | +10.5% |
| Current Ratio | 6.21 | 2.84 | +3.37 |
| Debt / Equity | — | 0.28 | — |